SCHEMBL1639237

SCHEMBL1639237

CC(C)(C)c1c[c]c(O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
TYR P14679 1/20 0.48
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALOX15 P16050 1/20 0.43
MAPT P10636 3/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 2/20 0.39
ESR1 P03372 4/20 0.37
ESR2 Q92731 4/20 0.37
CYP3A4 P08684 2/20 0.37
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192097 0.79 ESR1 (0.61) ALDH1A1HPGDHSD17B10ALOX15MEN1
SCHEMBL3281904 0.79 NPC1 (0.38) LMNATYRALDH1A1HPGDHSD17B10
SCHEMBL930516 0.77 SHBG (0.57) LMNATYRALDH1A1HPGDHSD17B10
SCHEMBL21268187 0.76 KIF11 (0.43) ALDH1A1TSHRESR1ESR2
SCHEMBL227931 0.73 TSHR (0.40) LMNATYRALDH1A1HPGDHSD17B10
SCHEMBL1550638 0.73 TSHR (0.46) LMNATYRALDH1A1HPGDHSD17B10
SCHEMBL930517 0.72 CNR2 (0.47)
SCHEMBL25227526 0.71 POLB (0.39) LMNATYRALDH1A1HPGDHSD17B10
SCHEMBL6225432 0.71 TSHR (0.39) LMNATYRALDH1A1HPGDHSD17B10
SCHEMBL17262489 0.71 TSHR (0.39) LMNATYRALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-6884815-B1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2005-04-26 US claimed
US-6783913-B2 POLYMERIC ACETAL RESIN CONTAINS UNITS (A), (B), (C), (D), AND (E). UNIT (A) IS A VINYL ALCOHOL UNIT. UNIT; (B) IS A POLYVINYL ACETAL UNIT CONTAINING AN R GROUP, WHERE R IS HYDROGEN, AN ALIPHATIC GROUP, AN AROMATIC GROUP, OR AN KODAK POLYCHROME GRAPHICS LLC 2004-08-31 US claimed
US-20030198887-A1 Polymeric acetal resins containing free radical inhibitors and their use in lithographic printing EASTMAN KODAK COMPANY 2003-10-23 US claimed
US-6436961-B1 SUBSTANCE P RECEPTOR ANTAGONIST; 2-PHENYL-3-BENZYLAMINOPIPERIDINES PFIZER INC 2002-08-20 US claimed
US-6174941-B1 FOR STABILIZING CHLORINE CONTAINING POLYMERS SUCH AS POLYVINYL CHLORIDE WITCO VINYL ADDITIVES GMBH (DE) 2001-01-16 US claimed
EP-0284174-B1 THERAPEUTIC PREPARATIONS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-07-29 EP claimed
US-9981910-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2018-05-29 US disclosed
EP-1910454-B2 TRIETHANOLAMINE PERCHLORATO (TRIFLATO) METAL INNER COMPLEX COORDINATION POLYMERS AS ADDITIVES FOR SYNTHETIC POLYMERS CATENA ADDITIVES GMBH & CO KG (DE) 2016-11-30 EP disclosed
CN-101248128-B Coordination polymeric triethanolamine perchloric acid (triflato) metal inner complexes as additives for synthetic polymers CATENA ADDITIVES GMBH & CO KG 2012-05-09 CN disclosed
CN-102136506-A Sealing film for solar battery module and manufacturing method thereof KASEI CO C I 2011-07-27 CN disclosed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-5173496-A Antiinflammatory agents ICI PHARMA (FR) 1992-12-22 US disclosed
CN-1046529-A Carbostyril derivative OTSUKA PHARMA CO LTD (JP) 1990-10-31 CN disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
US-4379876-A Methyl methacrylate-butadiene-styrene impact modifier polymers, polyvinyl chloride, compositions and methods ROHM AND HAAS COMPANY (US) 1983-04-12 US disclosed
US-4321191-A THIO-CONTAINING POLYESTERS, POLYCARBONATES, AND COMPOUNDS; HEAT RESISTANCE; DISCOLORATION INHIBITION; MECHANICAL PROPERTIES ARGUS CHEMICAL CORP. (US) 1982-03-23 US disclosed
US-3968102-A VASODILATOR, ANTICOAGULANT KOHJIN CO., LTD. (JA) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 LMNA 2595/4885TYR 3710/4885ALDH1A1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.